According to the latest IMARC Group report, "GCC Generic Injectables Market Report by Container Type (Vials, Prefilled Syringes, Ampoules, Premix, and Others), Therapeutic Area (Oncology, Anaesthesia, Anti-infectives, Cardiovascular, Parenteral Nutrition, and Others), Distribution Channel (Hospitals, Clinics, Retail Pharmacy Stores), and Region 2025-2033," the GCC generic injectables market size reached USD 761.0 Million in 2024. The generic injectable is a drug that is the bioequivalent of its branded counterparts and is not protected by drug patents. It consists of similar active ingredients, dosage, quality, and strength as their original counterparts, due to which its performance, intended use, quality, form, and route of administration are similar to that of the original equivalent. It offers various advantages, such as cost-effectiveness and better patient outcomes. Apart from this, it is safe and effective in the treatment of several chronic and life-threatening diseases, such as cancer, diabetes, cardiovascular ailments, respiratory infections and rheumatoid arthritis.
GCC Generic Injectables Market Trends:
The market in GCC is majorly driven by the increasing prevalence of chronic infectious diseases. In line with this, various pharmaceutical companies are heavily investing in research and development activities for manufacturing new generic injectables with increased efficacy, reduced adverse drug reactions, and improved patient output. Furthermore, the expiry of patents of various branded items and the decreasing number of new launches are positively influencing the market. Apart from this, the rising number of abbreviated new drug application (ANDA) approvals and the growing demand for inexpensive biosimilar products are catalyzing the market growth. Moreover, the increasing geriatric population and the rising prevalence of lifestyle disorders due to the sedentary lifestyles led by individuals are propelling the market. Besides, the governments of numerous countries across the GCC are undertaking efforts to offer their support to generic drug and injectable manufacturers. Additionally, rapid technological advancements in the manufacturing process of generic injectables are also providing a boost to the market. On account of the factors above, the market is anticipated to reach a value of USD 1,893.0 Million by 2033, exhibiting a CAGR of 10.7% during 2025-2033.
Market Summary:
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Million USD |
Segment Coverage | Container Type, Therapeutic Area, Distribution Channel, Country |
Countries Covered | Saudi Arabia, UAE, Kuwait, Qatar, Oman, Bahrain |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us:
IMARC Group
30 N Gould St, Ste
Sheridan, WY (Wyoming) 82801 USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800